Pluristem (PSTI) Announces Partnership with CPC Clinical Research for Study on Peripheral Artery Disease
Tweet Send to a Friend
Up)
Pluristem Therapeutics, Inc. (Nasdaq: PSTI) today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites. This partnership will leverage CPC's clinical study expertise, including patient recruitment, study monitoring, pharmacovigilance, site audits, quality assurance, biostatistics, data management and medical writing.
The IC study population will be comprised of 150 patients with Fontaine class IIb; Rutherford category 2-3 in a dose escalation, placebo controlled, double blinded study.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The IC study population will be comprised of 150 patients with Fontaine class IIb; Rutherford category 2-3 in a dose escalation, placebo controlled, double blinded study.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety and the Chairman of the Charite Berlin-Brandenburg Center for
- Janssen Pharma (JNJ) Plans Slew of Filing, Extension Submissions by FY17
- NewLead (NEWL) Receives Nasdaq Notice of Non-Compliance Over Late 20-F
Create E-mail Alert Related Categories
Corporate News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
